obstructive sleep apnea, FDA

In the trial that Lilly, the drug's manufacturer, submitted in April to the FDA, scientists reported that the drug helped ...
Sleep apnea can significantly increase health risks ... The drug's active ingredient, tirzepatide, is marketed as Zepbound for weight loss and Mounjaro as a diabetes treatment.
Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...
The FDA's approval of tirzepatide for the treatment of obstructive sleep apnea is based on a randomized, double-blind, placebo-controlled study in 469 adults without type 2 diabetes, in which ...